Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long non-coding RNA MALAT1

•Hsa-miR-125b and SIRT7/MALAT1 are inversely expressed in bladder cancer.•Hsa-miR-125b inhibits bladder cancer cell growth and motility, and increases apoptosis.•Hsa-miR-125b downregulates oncogene SIRT7 in bladder cancer.•Hsa-miR-125b downregulates oncogenic long non-coding RNA MALAT1 in bladder ca...

Full description

Saved in:
Bibliographic Details
Published in:FEBS letters 2013-11, Vol.587 (23), p.3875-3882
Main Authors: Han, Yonghua, Liu, Yuchen, Zhang, Hu, Wang, Tiantian, Diao, Ruiying, Jiang, Zhimao, Gui, Yaoting, Cai, Zhiming
Format: Article
Language:English
Subjects:
Apoptosis
Bladder cancer
Carcinoma - genetics
Carcinoma - metabolism
Carcinoma - pathology
Cell Line, Tumor
Cell Proliferation
Gene Expression Regulation, Neoplastic
HEK293 Cells
Hsa-miR-125b
Humans
Long non-coding RNA
MALAT1
MicroRNA
MicroRNAs - metabolism
RNA, Long Noncoding - metabolism
SIRT7
Sirtuins - metabolism
Transcription, Genetic
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - metabolism
Urinary Bladder Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Hsa-miR-125b and SIRT7/MALAT1 are inversely expressed in bladder cancer.•Hsa-miR-125b inhibits bladder cancer cell growth and motility, and increases apoptosis.•Hsa-miR-125b downregulates oncogene SIRT7 in bladder cancer.•Hsa-miR-125b downregulates oncogenic long non-coding RNA MALAT1 in bladder cancer.•Hsa-miR-125b suppresses bladder cancer development via inhibiting SIRT7 and MALAT1. MicroRNAs mainly inhibit coding genes and long non-coding RNA expression. Here, we report that hsa-miR-125b and oncogene SIRT7/oncogenic long non-coding RNA MALAT1 were inversely expressed in bladder cancer. Hsa-miR-125b mimic down-regulated, whereas hsa-miR-125b inhibitor up-regulated the expression of SIRT7 and MALAT1. Binding sites were confirmed between hsa-miR-125b and SIRT7/MALAT1. Up-regulation of hsa-miR-125b or down-regulation of SIRT7 inhibited proliferation, motility and increased apoptosis. The effects of up-regulation of hsa-miR-125b were similar to that of silencing MALAT1 in bladder cancer as we had previously described. These data suggest that hsa-miR-125b suppresses bladder cancer development via inhibiting SIRT7 and MALAT1.
ISSN:0014-5793
1873-3468
DOI:10.1016/j.febslet.2013.10.023